Pronóstico del mercado de terapias contra el cáncer de mama en América del Sur y Central hasta 2030 – Análisis regional – por terapia farmacológica [terapia farmacológica dirigida (abemaciclib, ado-trastuzumab emtansina, palbociclib, trastuzumab y otras terapias farmacológicas objetivo), terapia farmacológica hormonal (moduladores selectivos del receptor de estrógeno, inhibidores de la aromatasa y reguladores negativos selectivos de los receptores de estrógeno), quimioterapia e inmunoterapia/terapia biológica], tipo de cáncer de mama (receptor hormonal, HER2+ y cáncer de mama triple negativo) y canal de distribución (farmacias hospitalarias, farmacias y farmacias minoristas, y Farmacias en línea)
Aumento del uso de combustibles de medicina personalizada, el mercado terapéutico del cáncer de mama de América del Sur y Central
La medicina personalizada implica adaptar los planes de tratamiento a cada paciente en función de su composición genética, entre otros factores. Este enfoque permite tratamientos altamente específicos y eficaces, ya que considera las características únicas del cáncer de cada paciente. Los avances en genómica y diagnóstico molecular han hecho de la medicina personalizada una opción viable en el tratamiento del cáncer de mama. Los proveedores de atención médica pueden identificar mutaciones genéticas específicas o biomarcadores que impulsan el crecimiento del cáncer analizando el tumor de un paciente a nivel molecular. Luego, esta información se puede utilizar para seleccionar las opciones de tratamiento más adecuadas, como terapias dirigidas o inmunoterapias, que probablemente sean las más efectivas para ese paciente en particular. El uso de la medicina personalizada en la terapéutica del cáncer de mama tiene el potencial de mejorar significativamente los resultados de los pacientes. Por ejemplo, en febrero de 2022, investigadores de los NIH desarrollaron un enfoque de terapia personalizada contra el cáncer de mama, una forma experimental de inmunoterapia que utiliza células inmunitarias que combaten tumores de pacientes para tratar a aquellas con cáncer de mama metastásico, avanzando en la medicina personalizada.
Descripción general del mercado de terapias contra el cáncer de mama en América del Sur y Central
El mercado de terapias contra el cáncer de mama en América del Sur y Central está segmentado en Brasil, Argentina y el resto de América del Sur y Central. Se espera que Brasil tenga una participación importante en esta región. También se prevé que crezca a la tasa de crecimiento más alta. La creciente prevalencia del cáncer de mama, el envejecimiento de la población y el aumento del gasto en atención sanitaria per cápita se encuentran entre los factores que se espera que impulsen rápidamente el mercado de terapias contra el cáncer de mama.
La creciente prevalencia del cáncer de mama en Brasil impulsa la demanda de terapias contra el cáncer de mama. El cáncer de mama es la neoplasia maligna más prevalente en las mujeres en Brasil, según Nature Publications. Según el Instituto Nacional del Cáncer (INCA), cada año se identifican en Brasil aproximadamente 66.200 nuevos casos de cáncer de mama en mujeres, lo que se traduce en una tasa de incidencia estandarizada por edad de 43,74/100.000 mujeres.
La mejora de la infraestructura sanitaria y el acceso a tecnologías médicas avanzadas en Brasil también impulsan el mercado. El gobierno ha estado invirtiendo en ampliar las instalaciones de atención médica y mejorar el acceso a los servicios de atención médica, incluida la detección y el tratamiento del cáncer de mama. Esto ha llevado a la detección temprana de casos de cáncer de mama y ha aumentado la demanda de terapias. Por lo tanto, la creciente prevalencia del cáncer de mama, la mejora de la infraestructura sanitaria y la mayor concienciación sobre el cáncer de mama son factores clave que impulsan el mercado de terapias contra el cáncer de mama en Brasil.
Ingresos y pronóstico del mercado de terapias contra el cáncer de mama de América del Sur y Central hasta 2030 (millones de dólares estadounidenses)
Segmentación del mercado de terapias contra el cáncer de mama de América del Sur y Central
América del Sur y Central El mercado de terapias contra el cáncer de mama está segmentado según la terapia farmacológica, el tipo de cáncer de mama y el canal de distribución.
Basado en la terapia farmacológica, el mercado terapéutico del cáncer de mama de América del Sur y Central se segmenta en terapia farmacológica dirigida, terapia farmacológica hormonal, quimioterapia e inmunoterapia/terapia biológica. El segmento de terapia con medicamentos dirigidos tuvo una participación mayor en 2022. El segmento de terapia con medicamentos dirigidos tuvo una participación mayor en 2022. El segmento de terapia con medicamentos dirigidos se subsegmenta además en abemaciclib, ado-trastuzumab emtansina, palbociclib, trastuzumab y otros tratamientos con medicamentos dirigidos. Además, el segmento de la terapia con medicamentos hormonales se clasifica en moduladores selectivos de los receptores de estrógeno, inhibidores de la aromatasa y reguladores negativos selectivos de los receptores de estrógeno.
En términos de tipo de cáncer de mama, el mercado terapéutico para el cáncer de mama de América del Sur y Central está segmentado en receptor hormonal, HER2+ y cáncer de mama triple negativo. El segmento de receptores hormonales tuvo una participación mayor en 2022.
Por canal de distribución, el mercado terapéutico del cáncer de mama de América del Sur y Central se segmenta en farmacias hospitalarias, farmacias minoristas y de farmacias, y farmacias en línea. El segmento de farmacias hospitalarias tuvo una participación mayor en 2022.
Según el país, el mercado terapéutico del cáncer de mama de América del Sur y Central se clasifica en Brasil, Argentina y el resto de América del Sur y Central. Brasil dominó el mercado terapéutico contra el cáncer de mama en América del Sur y Central en 2022.
Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd y Amgen Inc son algunas de las empresas líderes que operan en el mercado terapéutico del cáncer de mama de América del Sur y Central.
Table of Content
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Breast Cancer Therapeutics Market - Key Industry Dynamics
4.1 Key Market Drivers
4.1.1 Growing Burden of Breast Cancer
4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:
5. Breast Cancer Therapeutics Market - South & Central America Market Analysis
5.1 South & Central America Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
6. South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Drug Therapy
6.1 Overview
6.2 South & Central America Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
6.3.1 Overview
6.3.2 Targeted Drug Therapy: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 South & Central America Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
6.4.1 Overview
6.4.2 Hormonal Drug Therapy: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 South & Central America Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
6.5.1 Overview
6.5.2 Chemotherapy: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
6.6.1 Overview
6.6.2 Immunotherapy/ Biological Therapy: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Breast Cancer Type
7.1 Overview
7.2 South & Central America Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
7.3.1 Overview
7.3.2 Hormone Receptor: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
7.4.1 Overview
7.4.2 HER2+: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
7.5.1 Overview
7.5.2 Triple-Negative Breast Cancer: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Distribution Channel
8.1 Overview
8.2 South & Central America Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
8.4.1 Overview
8.4.2 Drug Store and Retail Pharmacies: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. South & Central America Breast Cancer Therapeutics Market -Country Analysis
9.1 South & Central America Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
9.1.1 Overview
9.1.2 South & Central America Breast Cancer Therapeutics Market, Breakdown, by Country -Revenue (2022) (US$ Million)
9.1.3 South & Central America Breast Cancer Therapeutics Market, By Countries, 2022 and 2030 (%)
9.1.3.1 Brazil
9.1.3.1.1 Brazil Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.2 Brazil: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.1 Brazil: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.2 Brazil: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.3 Brazil: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.1.4 Brazil: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.2 Argentina
9.1.3.2.1 Argentina Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.2 Argentina: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.1 Argentina: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.2 Argentina: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.3 Argentina: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.2.4 Argentina: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.3 Rest of South & Central America
9.1.3.3.1 Rest of South & Central America Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.2 Rest of South & Central America: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.1 Rest of South & Central America: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.2 Rest of South & Central America: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.3 Rest of South & Central America: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.3.4 Rest of South & Central America: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Breast Cancer Therapeutics Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Eli Lilly and Co
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eisai Co Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Novartis AG
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 AstraZeneca Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Pfizer Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Gilead Sciences Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Merck & Co Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Amgen Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
List of Tables
Table 1. South & Central America Breast Cancer Therapeutics Market Segmentation
Table 2. South & Central America Breast Cancer Therapeutics Market, by Targeted Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 3. South & Central America Breast Cancer Therapeutics Market, by Hormonal Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 4. Brazil Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 5. Brazil Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 6. Brazil Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 7. Brazil Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 8. Brazil Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 9. Argentina Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 10. Argentina Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 11. Argentina Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 12. Argentina Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 13. Argentina Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 14. Rest of South & Central America Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 15. Rest of South & Central America Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 16. Rest of South & Central America Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 17. Rest of South & Central America Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 18. Rest of South & Central America Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 19. Recent Organic Growth Strategies in Breast Cancer Therapeutics Market
Table 20. Recent Inorganic Growth Strategies in the Breast Cancer Therapeutics Market
Table 21. Glossary of Terms, Breast Cancer Therapeutics Market
List of Figures
Figure 1. South & Central America Breast Cancer Therapeutics Market Segmentation, By Country
Figure 2. South & Central America Breast Cancer Therapeutics Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. South & Central America Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
Figure 5. South & Central America Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
Figure 6. Targeted Drug Therapy: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Hormonal Drug Therapy: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Chemotherapy: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Immunotherapy/ Biological Therapy: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. South & Central America Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
Figure 11. Hormone Receptor: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. HER2+: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Triple-Negative Breast Cancer: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. South & Central America Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
Figure 15. Hospital Pharmacies: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Drug Store and Retail Pharmacies: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Online Pharmacies: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. South & Central America Breast Cancer Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 19. South & Central America Breast Cancer Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 20. Brazil Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Argentina Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Rest of South & Central America Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Growth Strategies in Breast Cancer Therapeutics Market
1. Eli Lilly and Co
2. Eisai Co Ltd
3. Novartis AG
4. AstraZeneca Plc
5. Pfizer Inc
6. Gilead Sciences Inc
7. Merck & Co Inc
8. Teva Pharmaceutical Industries Ltd
9. Amgen Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America breast cancer therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in South & Central America breast cancer therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution